AU2021241718B2 - mTORC1 modulators and uses thereof - Google Patents

mTORC1 modulators and uses thereof Download PDF

Info

Publication number
AU2021241718B2
AU2021241718B2 AU2021241718A AU2021241718A AU2021241718B2 AU 2021241718 B2 AU2021241718 B2 AU 2021241718B2 AU 2021241718 A AU2021241718 A AU 2021241718A AU 2021241718 A AU2021241718 A AU 2021241718A AU 2021241718 B2 AU2021241718 B2 AU 2021241718B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
compound
salt
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021241718A
Other languages
English (en)
Other versions
AU2021241718A1 (en
Inventor
John Kincaid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeovian Pharmaceuticals Inc
Original Assignee
Aeovian Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeovian Pharmaceuticals Inc filed Critical Aeovian Pharmaceuticals Inc
Publication of AU2021241718A1 publication Critical patent/AU2021241718A1/en
Application granted granted Critical
Publication of AU2021241718B2 publication Critical patent/AU2021241718B2/en
Priority to AU2025204768A priority Critical patent/AU2025204768C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Burglar Alarm Systems (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
AU2021241718A 2020-03-27 2021-03-26 mTORC1 modulators and uses thereof Active AU2021241718B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204768A AU2025204768C1 (en) 2020-03-27 2025-06-25 Mtorc1 modulators and uses thereof

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063001177P 2020-03-27 2020-03-27
US202063001144P 2020-03-27 2020-03-27
US202063001187P 2020-03-27 2020-03-27
US63/001,177 2020-03-27
US63/001,144 2020-03-27
US63/001,187 2020-03-27
US202063019176P 2020-05-01 2020-05-01
US63/019,176 2020-05-01
US202063054762P 2020-07-21 2020-07-21
US202063054768P 2020-07-21 2020-07-21
US202063054763P 2020-07-21 2020-07-21
US63/054,762 2020-07-21
US63/054,768 2020-07-21
US63/054,763 2020-07-21
PCT/US2021/024536 WO2021195599A1 (en) 2020-03-27 2021-03-26 Mtorc1 modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204768A Division AU2025204768C1 (en) 2020-03-27 2025-06-25 Mtorc1 modulators and uses thereof

Publications (2)

Publication Number Publication Date
AU2021241718A1 AU2021241718A1 (en) 2022-10-20
AU2021241718B2 true AU2021241718B2 (en) 2025-03-27

Family

ID=77892684

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021241718A Active AU2021241718B2 (en) 2020-03-27 2021-03-26 mTORC1 modulators and uses thereof
AU2025204768A Active AU2025204768C1 (en) 2020-03-27 2025-06-25 Mtorc1 modulators and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204768A Active AU2025204768C1 (en) 2020-03-27 2025-06-25 Mtorc1 modulators and uses thereof

Country Status (11)

Country Link
US (3) US11634432B2 (enExample)
EP (1) EP4126229A4 (enExample)
JP (2) JP7606591B2 (enExample)
KR (2) KR102805250B1 (enExample)
CN (2) CN115776907B (enExample)
AU (2) AU2021241718B2 (enExample)
CA (1) CA3173722A1 (enExample)
IL (1) IL296828A (enExample)
MX (1) MX2022011964A (enExample)
WO (1) WO2021195599A1 (enExample)
ZA (1) ZA202210888B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CA3127448C (en) 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
EP4069223A4 (en) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
CN121426814A (zh) * 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途
WO2024211738A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110953A1 (en) * 2011-02-16 2012-08-23 Novartis Ag Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
WO2019064182A1 (en) * 2017-09-26 2019-04-04 Novartis Ag RAPAMYCIN DERIVATIVES

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
BR9408323A (pt) 1993-12-17 1997-08-19 Sandoz Ag Derivados de rapamicina
US6187757B1 (en) * 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
WO1999036553A2 (en) * 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
IL147803A0 (en) * 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
EP1896075A2 (en) 2005-06-22 2008-03-12 LifeCycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
WO2009131631A1 (en) 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
WO2014153118A1 (en) * 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
WO2015142661A1 (en) * 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
EP3193902A4 (en) 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
US20190022073A1 (en) 2015-09-03 2019-01-24 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
US10683308B2 (en) * 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN108926533B (zh) 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
US10478561B2 (en) 2017-08-03 2019-11-19 Minhong Yu Wireless transmission system with integrated sensing capability
US10980784B2 (en) * 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020076738A2 (en) 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
LT3898637T (lt) 2018-12-18 2025-03-10 Novartis Ag Rapamicino dariniai
CA3127448C (en) 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
EP4069223A4 (en) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
CN121426814A (zh) 2020-07-21 2026-01-30 艾奥维安制药公司 Mtorc1调节剂及其用途
JP2024503898A (ja) 2021-01-22 2024-01-29 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110953A1 (en) * 2011-02-16 2012-08-23 Novartis Ag Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
WO2019064182A1 (en) * 2017-09-26 2019-04-04 Novartis Ag RAPAMYCIN DERIVATIVES

Also Published As

Publication number Publication date
US11603377B2 (en) 2023-03-14
KR20250065937A (ko) 2025-05-13
WO2021195599A1 (en) 2021-09-30
JP7645431B2 (ja) 2025-03-13
CN119954829A (zh) 2025-05-09
MX2022011964A (es) 2022-12-02
KR20230084095A (ko) 2023-06-12
KR102805250B1 (ko) 2025-05-08
AU2025204768B2 (en) 2025-08-07
EP4126229A4 (en) 2024-04-17
KR102963519B1 (ko) 2026-05-11
AU2025204768C1 (en) 2026-02-05
IL296828A (en) 2022-11-01
US20220332727A1 (en) 2022-10-20
US11634432B2 (en) 2023-04-25
AU2025204768A1 (en) 2025-07-17
JP2025028197A (ja) 2025-02-28
BR112022019508A2 (pt) 2022-11-16
JP7606591B2 (ja) 2024-12-25
JP2023530778A (ja) 2023-07-19
US20220235069A1 (en) 2022-07-28
AU2021241718A1 (en) 2022-10-20
US20240002399A1 (en) 2024-01-04
ZA202210888B (en) 2024-02-28
CA3173722A1 (en) 2021-09-30
CN115776907A (zh) 2023-03-10
EP4126229A1 (en) 2023-02-08
CN115776907B (zh) 2025-02-25

Similar Documents

Publication Publication Date Title
AU2025204768C1 (en) Mtorc1 modulators and uses thereof
CA3257281A1 (en) PYRIMIDINE-BASED MODULATORS AND THEIR USES
WO2024259169A1 (en) Pyrimidine based modulators and uses thereof
IL323257A (en) KRAS modulators and their uses
CA3247639A1 (en) CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
EP4185590A2 (en) Mtorc1 modulators and uses thereof
ES3014225T3 (en) Rapamycin derivatives
CA3120514A1 (en) Cyclic ureas
CN116783183A (zh) 作为vhl抑制剂用于治疗贫血和癌症的1-(2-(4-环丙基-1h-1,2,3-三唑-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物
EP3112369A1 (en) Fused pyrazole derivative having autotaxin inhibitory activity
CN118307519A (zh) 一类cyp11a1抑制剂化合物及其制备方法和用途
BR122024006050B1 (pt) MODULADORES DE mTORC1 E SEUS USOS
BR112022019508B1 (pt) MODULADORES DE mTORC1 E SEUS USOS
BR122024006050A2 (pt) Moduladores de mtorc1 e seus usos
HK40096020A (en) Mtorc1 modulators and uses thereof
HK40096020B (zh) Mtorc1调节剂及其用途
TW202537962A (zh) 抑制α-V β-1整合素
WO2024178335A2 (en) Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)